Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2024 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
January 12, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
November 02, 2022 16:02 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...
October 21, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
October 12, 2022 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that...
April 11, 2022 07:00 ET | Source: BioNTech SE

BioNTech und Matinas BioPharma geben exklusive Forschungskollaboration zur Entwicklung neuer Formulierungen für mRNA-basierte Impfstoffe bekannt

Exklusive Forschungskollaboration kombiniert BioNTech’s Expertise in der Entwicklung mRNA-basierter Impfstoffe mit Matinas Lipid-Nanokristall (LNC)-Plattformtechnologie zur Entwicklung...
April 11, 2022 07:00 ET | Source: BioNTech SE

BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines

Exclusive collaboration combines BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines,...